Filtering

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 146 ()

1Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Pediatrics, Seoul, South Korea 2Samsung Medical Center, Biostatistics and Clinical Epidemiology Center, Seoul, South Korea 3Chungbuk National University Hospital, Chungbuk National University College of Medicine, Department of Pediatrics, Cheongju, South Korea

DOP031

Subtherapeutic serum infliximab trough levels and complete mucosal healing are associated with sustained clinical remission after infliximab discontinuation in paediatric Crohn's disease patients

Year: 2017
Source:

1Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Pediatrics, Seoul, South Korea 2Samsung Medical Center, Biostatistics and Clinical Epidemiology Center, Seoul, South Korea 3Chungbuk National University Hospital, Chungbuk National University College of Medicine, Department of Pediatrics, Cheongju, South Korea

Authors:

Kang B.*1, Lee K.1, Kim K.2, Lee J.H.3, Choe Y.H.1

1Saint Louis Hospital, Gastroenterology, Paris, France 2INSERM, U940, Paris, France 3Institut Montsouris, Gastroenterology, Paris, France 4Saint Louis Hospital, Pharmacology, Paris, France

DOP032

Hydrocortisone premedication withdrawal in patients on stable infliximab maintenance: clinical and pharmacokinetic outcomes

Year: 2017
Source:

1Saint Louis Hospital, Gastroenterology, Paris, France 2INSERM, U940, Paris, France 3Institut Montsouris, Gastroenterology, Paris, France 4Saint Louis Hospital, Pharmacology, Paris, France

Authors:

Tran-Minh M.-L.*1, Maillet M.1, Auzolle C.1,2, Simon M.3, Cathala A.L.1, Aparicio T.1,2, Baudry C.1, Bonnet J.1, Lourenco N.1, Houze P.4, Gornet J.-M.1, Allez M.1,2

DOP032

Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safe

Year: 2016
Authors:

M. Kolar*1, D. Duricová2, M. Brotlik1, V. Hruba1, N. Machkova1, K. Mitrova1, K. Malickova3, M. Lukas1, M. Lukas1

1Charles University, IBD Clinical and Research Centre, ISCARE, Prague, Czech Republic, 2Charles University, IBD Clinical and Research Centre, Iscare, Prague, Czech Republic, 3 First Medical Faculty and General Teaching Hospital, Charles University, Institute of Medical Biochemistry and Laboratory Diagnostics, Prague, Czech Republic

DOP033

Immunogenicity profile and predictors of TLs and ADA development of biosimilar infliximab during the first 6 months of the therapy: results from a prospective nationwide cohort

Year: 2016
Authors:

B. Lovasz*1, Z. Kurti1, M. Rutka2, Z. Vegh1, K. Gecse1, K. Farkas2, J. Banai3, L. Bene4, B. Gasztonyi5, T. Kristof6, L. Lakatos7, P. Miheller8, K. Palatka9, A. Patai10, A. Salamon11, T. Szamosi3, Z. Szepes12, E. Biro13, G.T. Toth14, A. Vincze15, T. Molnar2, P. Lakatos1

1Semmelweis University, First Department of Medicine, Budapest, Hungary, 2University of Szeged, First Department of Medicine, Szeged, Hungary, 3Military Hospital, State Health Centre, Department of Gastroenterology, Budapest, Hungary, 4Peterfy Hospital, First Department of Medicine, Budapest, Hungary, 5Zala County Hospital, Second Department of Medicine, Zalaegerszeg, Hungary, 6B-A-Z County and University Teaching Hospital, Second Department of Medicine, Miskolc, Hungary, 7Csolnoky F. Province Hospital, Department of Medicine, Veszprem, Hungary, 8Semmelweis University, Second Department of Medicine, Budapest, Hungary, 9University of Debrecen, Institute of Medicine, Department of Gastroenterology, Debrecen, Hungary, 10Markusovszky Hospital, First Department of Medicine and Gastroenterology, Szombathely, Iceland, 11Tolna County Teaching Hospital, First Department of Gastroenterology, Szekszard, Hungary, 12University of Szeged, First Department of Internal Medicine, Szeged, Hungary, 13Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary, 14Janos Hospital, Department of Gastroenterology, Budapest, Hungary, 15University of Pécs, First Department of Medicine, Pécs, Hungary

1University of California, San Diego, United States 2Robarts Clinical Trials, Inc., San Diego, United States 3University of Western Ontario, London, Canada 4Robarts Clinical Trials, Inc., London, Canada

DOP033

Severely active ulcerative colitis is associated with high baseline infliximab clearance, reduced serum half-life and worse endoscopic outcomes

Year: 2017
Source:

1University of California, San Diego, United States 2Robarts Clinical Trials, Inc., San Diego, United States 3University of Western Ontario, London, Canada 4Robarts Clinical Trials, Inc., London, Canada

Authors:

Vande Casteele N.*1,2, Jairath V.3,4, Levesque B.1,2, Feagan B.3,4, Sandborn W.1,2

DOP034

Comparative effectiveness of infliximab and adalimumab in Crohns disease: results from a real-life population-based cohort

Year: 2016
Authors:

S. Jeuring*1, 2, D. Wintjens1, T. Van den Heuvel1, 2, M. Zeegers3, 4, 
W. Hameeteman1, M. Romberg-Camps5, L. Oostenbrug6, A. Masclee1, 2, D. Jonkers1, 2, M. Pierik1, 2

1Maastricht University Medical Centre, Internal Medicine - Division of Gastroenterology and Hepatology, Maastricht, Netherlands, 2Maastricht University Medical Centre, NUTRIM - School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands, 3Maastricht University Medical Centre, Complex Genetics - School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht, Netherlands, 4Maastricht University Medical Centre, CAPHRI - School for Public Health and Primary Care, Maastricht, Netherlands, 5Zuyderland Medical Centre, Internal Medicine and Gastroenterology-Hepatology, Sittard-Geleen, Netherlands, 6Zuyderland Medical Centre, Internal Medicine and Gastroenterology-Hepatology, Heerlen, Netherlands

1CHU St Eloi, Hepato-gastro-enterology, Montpellier, France 2CHU Nimes, Hepato-Gastro-Enterology, Nimes, France

DOP034

Serum adalimumab concentration 3 months after surgery is correlated with endoscopic recurrence in Crohn's disease patients treated with adalimumab for prevention of postoperative recurrence

Year: 2017
Source:

1CHU St Eloi, Hepato-gastro-enterology, Montpellier, France 2CHU Nimes, Hepato-Gastro-Enterology, Nimes, France

Authors:

Boivineau L.*1, Bourgaux J.F.2, Pineton de Chambrun G.1, Caillo L.2, Danan G.1, Boitard J.1, Liautard J.1, Guillon F.1, Altwegg R.1

Kliniken Essen Mitte, Gastroenterology, Essen, Germany

DOP035

High gammaglobulin and low albumin serum levels independently predict secondary loss of response to anti-TNFα therapy in IBD

Year: 2017
Source:

Kliniken Essen Mitte, Gastroenterology, Essen, Germany

Authors:

Schoenefuss F., Hoffmann P.

DOP035

Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα –blocking agents

Year: 2016
Authors:

P. Molander*1, 2, M. Färkkilä2, 3, H. Kemppainen4, T. Blomster5, A. Jussila6, H. Mustonen7, T. Sipponen2, 3

1Helsinki University Central Hospital, Peijas Hospital, Gastroenterology, Vantaa, Finland, 2University of Helsinki, Helsinki, Finland, 3Helsinki University Central Hospital, Abdominal Centre, Clinic of Gastroenterology, Helsinki, Finland, 4Turku University Central Hospital, Department of Gastroenterology, Turku, Finland, 5Oulu University Hospital, Department of Gastroenterology, Oulu, Finland, 6Tampere University Hospital, Department of Gastroenterology and Alimentary Tract Surgery, Tampere, Finland, 7Helsinki University Central Hospital, Department of Surgery, Helsinki, Finland

DOP036

Infliximab discontinuation is associated with a higher risk for relapse in patients with ulcerative colitis in remission: a multinational collaborative retrospective study

Year: 2016
Authors:

G. Fiorino*1, P. Ellul2, M. Muscat2, P. Karatzas3, M. Silva4, A. Peixoto4, C. Felice5, F. Bossa6, P.L. Lakatos7, S. Sebastian8, B. Ungar9, F. Furfaro1, K. Karmiris10, K.H. Katsanos11, P. Navarro Cortes12, M.M. Boscà Watts12, D.K. Christodoulou11, G. Maconi13, U. Kopylov9, A. Armuzzi5, F. Magro4, G. Mantzaris3, S. Ben-Horin9, S. Danese1, 14

1Humanitas Research Hospital, IBD Centre, Gastroenterology, Rozzano, Milan, Italy, 2Mater Dei Hospital, Department of Gastroenterology, Msida, Malta, 3Evangelismos Hospital, Department of Gastroenterology, Athens, Greece, 4Centro Hospitalar São João, Oporto, Portugal, Gastrenterology, Oporto, Portugal, 5Complesso Integrato Columbus, Gemelli Hospital Catholic University Foundation, IBD Unit, Rome, Italy, 6Casa Sollievo della Sofferenza Hospital, Division of Gastroenterology, San Giovanni Rotondo, Italy, 7Semmelweis University, 1st Department of Medicine, Budapest, Hungary, 8Hull & East Yorkshire NHS Trust, Hull & York Medical School, Hull, United Kingdom, 9Sheba Medical Centre, Gastroenterology, Tel Hashomer, Tel-Aviv, Israel, 10Venizelion General Hospital, Department of Gastroenterology, Heraklion, Greece, 11University Hospital of Ioannina - Greece, Department of Gastroenterology, Ioannina, Greece, 12University Clinic Hospital of Valencia, Department of Gastroenterology, Valencia, Spain, 13Luigi Sacco University Hospital, Department of Gastroenterology, Milan, Italy, 14Humanitas University, Department of Biomedical Sciences, Rozzano, Italy

DOP037

Excess steroid use in IBD: too much, how much, and why? Results from a UK nationwide audit

Year: 2016
Authors:

T. Raine1, A. Bassi2, E. Fogden3, B. Hayee4, J. K. Limdi5, H. Ludlow6, S. McLaughlin7, G. C. Parkes8, P. Patel9, M. Smith10, C. Selinger*11

1Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Department of Gastroenterology Research, Cambridge, United Kingdom, 2Whiston Hospital, Department of Gastroenterology, Prescot, United Kingdom, 3Sandwell District General Hospital, Department of Gastroenterology, West Bromwich, United Kingdom, 4King’s College Hospital, Department of Gastroenterology, London, United Kingdom, 5Pennine Acute Hospitals NHS Trust, Department of Gastroenterology, Manchester, United Kingdom, 6University Hospital Llandough, Department of Gastroenterology, Penarth, Cardiff, United Kingdom, 7Royal Bournemouth Hospital, Department of Gastroenterology, Bournemouth, United Kingdom, 8Barts and The London, Queen Mary’s School of Medicine and Dentistry, Department of Gastroenterology, London, United Kingdom, 9Epsom General Hospital, Department of Gastroenterology, Epsom, United Kingdom, 10Brighton and Sussex University Hospitals Trust, Digestive Diseases, Hove, East Sussex, United Kingdom, 11St James University Hospital, Gastroenterology, Leeds, United Kingdom

DOP038

Analytical and clinical validation of a rapid point-of-care assay for infliximab quantification in patients with ulcerative colitis

Year: 2016
Authors:

T. Van Stappen*1, L. Bollen1, N. Vande Casteele1, K. Papamichail1, 2, 
N. Geukens1, C. Barthel3, Y. Kölmel3, N. Zali3, S. Rameil3, G. Van Assche2, M. Ferrante2, S. Vermeire2, A. Gils1

1KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 2UZ Leuven, Department of Clinical and Experimental Medicine, Leuven, Belgium, 3R-Biopharm AG, Darmstadt, Germany

Jinling Hospital, Medical School of Nanjing University, Department of General Surgery, Nanjing, China

DOP038

Increased number of enteric glial cells in proximal margin of resection is associated with postoperative recurrence of Crohn's disease

Year: 2017
Source:

Jinling Hospital, Medical School of Nanjing University, Department of General Surgery, Nanjing, China

Authors:

Li Y., Zhu W., Gong J., Guo Z.

DOP039

Point-of-care monitoring of infliximab trough levels in capillary fingerstick blood of patients with inflammatory bowel disease (IBD)

Year: 2016
Authors:

J. Maljaars*1, C. de Dood2, S. van der Burg1, A. van der Meulen1, H. Tanke2, P. Corstjens2

1LUMC, Gastroenterology-Hepatology, Leiden, Netherlands, 2Leiden University Medical Centre, Department of Molecular Cell Biology Geb. 1, Leiden, Netherlands

DOP040

Effects of education and information on vaccination behaviour in IBD patients

Year: 2016
Authors:

S. Coenen*1, E. Weyts1, C. Jorissen2, P. De Munter3, M. Noman1, V. Ballet1, S. Vermeire1, G. Van Assche1, M. Ferrante1

1UZ Leuven, Gastroenterology, Leuven, Belgium, 2KU Leuven, Leuven, Belgium, 3UZ Leuven, Leuven, Belgium

DOP041

Impact of an education programme on IBD patients skills: one year results of the ECIPE randomised, controlled multicentre study.

Year: 2016
Authors:

J. Moreau1, L. Marthey2, C. Trang3, M. Nachury4, R. Altwegg5, J.-C. Grimaud6, S. Orempuller1, J. Filippi7, A. Aubourg8, C. Baudry9, P. Seksik10, X. Roblin11, S. Nahon12, G. Savoye13, B. Mesnard14, C. Stefanescu15, M. Simon16, B. Coffin17, J.-L. Dupas18, S. Chevret19, M. Allez*20

1Rangueil Hospital, Department of Gastroenterology, Toulouse, France, 2Bicetre Hospital, Department of Gastroenterology, Le Kremlin Bicêtre, France, 3CHU Hotel Dieu, Department of Gastroenterology, Nantes, France, 4Huriez Hospital, Department of Gastroenterology, Lille, France, 5Saint Eloi Hospital, Department of Hepatology and Gastroenterology, Montpellier, France, 6Nord Hospital, Department of Gastroenterology, Marseille, France, 7Archet Hospital, Department of Gastroenterology and Nutrition, Nice, France, 8Trousseau University Hospital, Department of Gastroenterology, Tours, France, 9Saint-Louis Hospital, Department of Gastroenterology and Hepatology, Paris, France, 10St. Antoine Hospital, Department of Gastroenterology, Paris, France, 11CHU St Etienne, Department of Gastroenterology, Saint-Etienne, France, 12Montfermeil Hospital, Department of Gastroenterology, Montfermeil, France, 13Charles Nicolle Hospital, Department of Gastroenterology, Rouen, France, 14CH Dron, Department of Gastroenterology, Tourcoing, France, 15Beaujon Hospital, Department of Gastroenterology, Paris, France, 16Montsouris Mutualist Institute, Department of Gastroenterology, Paris, France, 17Louis Mourier Hospital APHP, Department of Gastroenterology and Hepatology, Colombes, France, 18Nord Hospital, Department of Gastroenterology, Amiens, France, 19Saint-Louis Hospital, Department of Biostatistics, Paris, France, 20Saint-Louis Hospital, Department of Gastroenterology, Paris, France

DOP042

Most anti-TNF injectors are stored under suboptimal conditions at home

Year: 2016
Authors:

M. de Jong*1, 2, M. Pierik1, 2, A. Peters3, M. Roemers4, F. van der Heijden5, V. Hilhorst6, A. van Tubergen7, 8

1Maastricht University Medical Centre+, Department of Internal Medicine, division of Gastroenterology and Hepatology, Maastricht, Netherlands, 2Maastricht University Medical Centre+, NUTRIM – School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands, 3Maastricht University Medical Centre+, Department of Internal Medicine, Maastricht, Netherlands, 4AntTail, Utrecht, Netherlands, 5MSD, Haarlem, Netherlands, 6Maastricht University Medical Centre+, Department of Clinical Pharmacy & Toxicology, Maastricht, Netherlands, 7Maastricht University Medical Centre+, Department of Internal Medicine, division of Rheumatology, Maastricht, Netherlands, 8Maastricht University Medical Centre+, CAPHRI - School for Public Health and Primary Care, Maastricht, Netherlands

DOP043

Nonadherence to anti-TNF therapy predicts clinical outcomes in outpatients with inflammatory bowel disease: results from a prospective multicentre study

Year: 2016
Authors:

M. van der Have*1, B. Oldenburg1, A. A. Kaptein2, J. M. Jansen3, R. C. Scheffer4, S. A. van Tuyl5, A. E. van der Meulen - de Jong6, M. Pierik7, P. D. Siersema1, M. G. van Oijen1, 8, H. H. Fidder1

1University Medical Centre Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands, 2Leiden University Medical Centre, Section Medical Psychology, Leiden, Netherlands, 3Onze Lieve Vrouwe Gasthuis, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, 4Jeroen Bosch Hospital, Department of Gastroenterology and Hepatology, ‘s Hertogenbosch , Netherlands, 5Diakonessenhuis, Department of Gastroenterology and Hepatology, Utrecht, Netherlands, 6Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands, 7Maastricht University Medical Centre, Department of Gastroenterology and Hepatology, Maastricht, Netherlands, 8Academic Medical Centre, Department of Medical Oncology, Amsterdam, Netherlands

DOP044

Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease

Year: 2016
Authors:

K. Carlsen*1, 2, C. Jakobsen2, L. F. Hansen2, A. Paerregaard2, L. B. Riis3, P. S. Munkholm4, V. Wewer2

1Hvidovre Hospital, Paediatric, Hvidovre, Denmark, 2Hvidovre Hospital, Department of Paediatrics, Hvidovre, Denmark, 3Herlev Hospital, Department of Pathology, Herlev, Denmark, 4North Zealand Hospital, Department of Gastroenterology, Frederikssund, Denmark

1CHU Rouen, Department of Gastroenterology and Hepatology, Rouen, France 2CHRU Lille, Department of Biostatistics EA 2694, Lille, France 3Amiens University Hospital, Department of Gastroenterology and Hepatology, Amiens, France 4CHRU Lille, Department of Epidemiology, Lille, France 5CH Seclin, Department of Gastroenterology, Seclin, France 6CHRU Lille, Department of Gastroenterology, Lille, France 7CHU Nancy, Department of Gastroenterology and Hepatology, Vandoeuvre-Lès-Nancy, France 8CHRU Lille, Department of Epidemiology, EPIMAD Registry, Lille, France

DOP045

Post-operative complications in elderly-onset inflammatory bowel disease: a population-based study

Year: 2017
Source:

1CHU Rouen, Department of Gastroenterology and Hepatology, Rouen, France 2CHRU Lille, Department of Biostatistics EA 2694, Lille, France 3Amiens University Hospital, Department of Gastroenterology and Hepatology, Amiens, France 4CHRU Lille, Department of Epidemiology, Lille, France 5CH Seclin, Department of Gastroenterology, Seclin, France 6CHRU Lille, Department of Gastroenterology, Lille, France 7CHU Nancy, Department of Gastroenterology and Hepatology, Vandoeuvre-Lès-Nancy, France 8CHRU Lille, Department of Epidemiology, EPIMAD Registry, Lille, France

Authors:

Sacleux S.-c.*1, Charpentier C.1, Sarter H.2, Fumery M.3, Guillon-Dellac N.4, Laberenne E.5, Pariente B.6, Peyrin-biroulet L.7, Gower-Rousseau C.8, Savoye G.1

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 146 ()